Moon Surgical (Paris and San Francisco) announced today that it has raised $31.3 million in Series A funding to expand its team and accelerate the development of its Maestro robotic surgery system.
GT Healthcare Capital & Partners led the round. There was also participation from Johnson & Johnson Innovation – JJDC, Cathay Health — and existing investors including Sofinnova Partners and medtech leaders including Yann Fleureau, Siddarth Satish, Sacha Loiseau and Richard Leparmentier.
“At Moon Surgical, our ambition is to revolutionize minimally invasive surgery through the power of collaborative and adaptive robotics. Our Maestro System can be used in any laparoscopy, in any operating room,” said Anne Osdoit, CEO of Moon Surgical and a partner in Sofinnova Partners’ medtech accelerator, MD Start.
“We are excited to work with our new partners at GT Healthcare, Johnson & Johnson, and Cathay Health as we enter the next stage of our company’s evolution,” Osdoit said in a news release.
The two-year-old company said it has early fully functional systems and driven by more than 30 surgeons across two continents and multiple clinical indications. The company’s goal behind Maestro is to have a system that is small, adaptable and integrated into existing clinical workflows. Call the Maestro a robotic surgical assistant.
“We share the vision of Maestro’s data-driven capabilities in underserved laparoscopic procedures, and hope to support its path in making robotic surgery accessible across all geographies,” said Alan Au, managing partner of GT Healthcare. He is joining Moon Surgical’s board.
Dr. Steve Oesterle, a former Medtronic SVP and venture partner at Cathay Health, said Maestro is about democratizing control during surgery. “We’re all very eager to support this global business in its development so that it can rapidly be used in many surgeries.”
Oesterle and Intuitive co-founder Dr. Fred Moll, chief development officer of J&J’s Auris Health, will serve as Moon Surgical board advisors.
